BioCentury
ARTICLE | Finance

Coasting on catalysts

Investors are watching CAR T, ASH, ophthalmology and Orphan therapies in 4Q17

October 6, 2017 11:10 PM UTC

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar.

But the biggest milestones on their minds are commercial milestones: the launches of chimeric antigen receptor T cell (CAR T) therapies Kymriah tisagenlecleucel from Novartis AG and Gilead Sciences Inc.’s newly acquired axicabtagene ciloleucel. ...